IGC PHARMA, INC.— Sankey Diagram

Quarterly mode · period ending 2025-09-30 · SEC EDGAR

ComparingFY2025 (Q1+Q2+Q3+Q4) vs FY2024 (Q1+Q2+Q3+Q4)
Revenue
$1M
↓-6.5% -$77Kvs FY2024 (Q1+Q2+Q3+Q4)
Gross Profit
$511K
↓-23.2% -$154Kvs FY2024 (Q1+Q2+Q3+Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
Reconciled values per the quarterly mode pipeline. Compare against SEC EDGAR filings.
Line itemFY2025 (Q1+Q2+Q3+Q4)FY2024 (Q1+Q2+Q3+Q4)
Revenue$1M$1M
COGS$595K$518K
Gross Profit$511K$665K
R&D$4M$4M
SG&A$4M$6M
D&A$571K$631K
Other OpEx$0$0
Operating Income$0$0
Interest Exp.$0$0
Other Non-Op$0$0
Pretax Income$0$0
Tax$0$0
Net Income$0$0

QuarterCharts · SEC EDGAR data · IGC · Comparing FY2025 (Q1+Q2+Q3+Q4) vs FY2024 (Q1+Q2+Q3+Q4)